Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3Breast 3Tumor-Agnostic 2Lymphoid 2Sarcoma 1Plasma cell 1Genitourinary 1

Conditions

Rectal Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × Immunoconjugates × Gastrointestinal × Clear all
NCT03255070 2024-02-01

A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)

Ambrx, Inc.

Phase 1 Completed
106 enrolled
BreastGastrointestinal

Breast Neoplasms, Stomach Neoplasms

NCT01605318 2024-01-24

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

Gilead Sciences

Phase 1/2 Terminated
92 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT01915472 2021-08-19

A Phase II Study of IMMU 130 in Patients With Metastatic Colorectal Cancer

Gilead Sciences

Phase 2 Withdrawn
Gastrointestinal

Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡